Fourteen TAAs (p53, p16, IMP2, IMP3, SOX2, BIRC5, HIF1-α, HSP60, ENO1, CTAG1B, MUC1, Her2, GAL1, and GAL3) that have been commonly reported to be targets of autoantibodies in various cancer types were used to profile their corresponding autoantibodies in patients with PCa. This evidence concerns the gene IMP3 and posterior cortical atrophy.